


## **Time to Market**

<b>Prevention Product</b>	2022
Vaginal Ring	Q1Q2Q3Multiple reg approvalsDapivirine monthlyWHO guidelines
<section-header></section-header>	Cabotegravir       Multappe         One intramuscular injection       Severy 2 months         Sime intramuscular injections       Severy 2 months         Lenacapavir       Two subcutaneous injections         Two subcutaneous injections       Severy 6 months
Oral Prep	F/TAF daily MK-8527 monthly
<image/>	Co-formulated TDF/FTC and ethinyl estradiol/ levonorgestrel oral contraceptive pill daily

## **Years Ahead in HIV Prevention Research**



5 202		0.1	2027				20	2
Q3 Q4 Q1 Q2	<ul> <li>Q3 Q4</li> <li>Demonst</li> <li>Unclear of</li> <li>Initial pr</li> <li>Oct 2023 reached</li> <li>3-month submitte</li> <li>Opporture</li> </ul>	demand a ice ~\$18 3: A mem on a prod ly ring is ed to regu	odest eff & limited 0 per ye lorandur duct lice currentl lators in	ficacy d initial s ear m of und ense wit y in dev 1 2025	derstanc h Kiara elopmer	ling h nt and	d cou	11
ts	<ul> <li>Demonst</li> <li>Unclear</li> <li>Initial LM</li> <li>March 20 submiss</li> <li>4-month submiss</li> <li>Opporture</li> </ul>	demand a IC price ~ D23: MPI ion to reg ly formul ion for re	& limited \$240/yr P & ViiV gulators ation is gulatory	d initial s ; in 2024 licensed by 2027 currentl approv	4 ~\$180 d to 3 ge 7 y in dev al expec	enerio elopr cted i	cs wit ment, in ear	th , ` rl <u>y</u>
Possible regulatory approvals	roduct intro	duction						•••
Possible regulatory approvals								
<b>Possible Phase 3</b> Possible Go/No-Go Decis	ion for Phase	e 3 in Q1	. 2025			0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		
Ρο	ssible prod	uct intro	oductio	n				
udy: HPTN 104								



